...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatitis B Annual >Telbivudine: A valuable treatment option in chronic hepatitis B
【24h】

Telbivudine: A valuable treatment option in chronic hepatitis B

机译：替比夫定：慢性乙型肝炎的一种有价值的治疗选择

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The last five years have emerged as a new era in the treatment of chronic hepatitis B (CHB). Advances in therapeutics and theapproval of new drugs have been accompanied by a better understanding of the natural history and pathogenesis, as well asbetter diagnostics. In the treatment of CHB, no therapy has been proven to eradicate the virus completely from the human bodydue to the persistence of the covalently closed circular hepatitis B virus (HBV) DNA in the hepatocytes. Long-term maximalviral suppression is of utmost importance for the prevention of disease progression and hepatocellular cirrhosis development.Telbivudine is one of the more potent options, with phase III studies indicating its antiviral potency with 6- to 6.5-log 10 copies /mL reductions in HBV DNA levels at year one, comparable to other potent agents such as entecavir or tenofovir. Theincreasing rates of hepatitis B e antigen (HBeAg) seroconversion were achieved in HBeAg-positive patients during periods ofup to four years of continuous telbivudine treatment, and seroconversion was durable in most patients throughout a two-year,off-treatment follow-up, indicating the potential for a finite treatment period in this group of patients. Long-term telbivudinetreatment offers effective viral suppression to CHB patients, with certain baseline characteristics and on-treatment virologicalresponse. It is also one of the few drugs in the treatment of CHB under FDA pregnancy Category B. Telbivudine is welltolerated,with elevations in creatine phosphokinase being the most common abnormality observed in the clinical trials. Mostoften, elevations have been asymptomatic. There are few new drugs for hepatitis B in the pipeline, with the agent farthest alongin development, clevudine, halted for problems with muscle toxicity. Future research in hepatitis B will focus on the best waysto use the existing therapies, including telbivudine, sequentially or in combination, in order to maximize viral suppression andminimize the development of antiviral resistance.
机译：最近的五年已成为治疗慢性乙型肝炎（CHB）的新时代。随着新疗法在治疗和批准方面的进步，人们对自然病史和发病机制以及更好的诊断方法有了更好的了解。在CHB的治疗中，由于肝细胞中共价闭合的环状乙型肝炎病毒（HBV）DNA的持续存在，尚未证明任何疗法可以从人体完全清除病毒。长期最大的病毒抑制作用对于预防疾病进展和肝细胞肝硬化的发展至关重要。替比夫定是更有效的选择之一，III期研究表明，它的抗病毒能力降低了6到6.5个对数10拷贝/ mL。第一年的HBV DNA水平与其他有效药物（例如恩替卡韦或替诺福韦）相当。在连续四年的替比夫定治疗期间，HBeAg阳性患者的乙型肝炎e抗原（HBeAg）血清转化率增加，并且在为期两年的非治疗随访中，大多数患者的血清转化率持久。该组患者有限治疗期的潜力。长期替比夫定治疗可为CHB患者提供有效的病毒抑制，具有一定的基线特征和治疗中的病毒学应答。它也是FDA怀孕类别B下治疗CHB的少数药物之一。替比夫定耐受性良好，肌酸磷酸激酶升高是临床试验中最常见的异常现象。通常，高程无症状。目前正在开发中的用于治疗乙型肝炎的新药寥寥无几，其中最遥远的药物是克列夫定，由于肌肉毒性问题而被停药。乙型肝炎的未来研究将集中于顺序或联合使用现有疗法（包括替比夫定）的最佳方法，以最大程度地抑制病毒并最小化抗病毒耐药性的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号